GlassScriptPhysician profile
Hector D Allende
NPI 1235237595
$1,144.92
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $14.70 · 2021: $347 · 2022: $617.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $587.69 | 2019-2022 | |
| Shionogi INC | $116.89 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.91 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $74.17 | 2021-2022 | |
| Redhill Biopharma INC. | $72.17 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.39 | 2022 | |
| Boston Scientific Corporation | $31.17 | 2022 | |
| Ferring Pharmaceuticals INC. | $23.20 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $18.84 | 2022 | |
| Gilead Sciences, INC. | $15.89 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $14.70 | 2020 | |
| Janssen Biotech, INC. | $10.90 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$4,680.03 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Allende listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.